Efficacy of Granulocyte Apheresis in Pediatric Patients With Ulcerative Colitis: A Pilot Study

Ikeda, Hitoshi; Ishimaru, Yuki; Takayasu, Hajime; Fujino, Junko; Kisaki, Yoshiyuki; Otani, Yushi; Yamagishi, Junko; Tahara, Kazunori

doi:10.1097/01.mpg.0000237928.07729.79

Cited by 19 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From the limited evidence so far, which mainly comes from Japan, the treatment has proved to be extremely safe also in this context 48–51. Recently, the results of some European studies have also been published, which confirm the safety of GMA in the treatment of pediatric patients with IBD 52,53.…”

Section: Safetymentioning

confidence: 91%

Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?

Vecchi¹,

Vernia²,

Riegler³

et al. 2013

CEG

View full text Add to dashboard Cite

Granulocyte-monocyte apheresis is a relatively new therapy that has been proposed, sometimes with controversial results, for the treatment of inflammatory bowel disease, particularly ulcerative colitis. The aim of the present study was to perform a thorough review of the literature on the application of this type of treatment in ulcerative colitis and discuss the results, in order to provide an opinion on its use which is shared by the involved experts. The review of the literature was performed by searching PubMed with appropriate key words. The results obtained suggest that the major role for this treatment at this moment is for those patients with steroid dependency or with major contraindications to use of steroids. However, promising, albeit very preliminary, results have also been observed in steroid-naïve subjects, and this is of particular interest in consideration of the safety profile of this therapeutic method. As such, the Adacolumn may prove useful in specific subgroups of patients. Future phenotypic, genotypic, and molecular characterization of patients with inflammatory bowel disease might prove useful in defining better those subjects who might benefit most from this treatment modality.

show abstract

Section: Safetymentioning

confidence: 91%

Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?

Vecchi¹,

Vernia²,

Riegler³

et al. 2013

CEG

View full text Add to dashboard Cite

show abstract

“…This can reduce the serious steroid-induced complications such as growth retardation, infection, and cosmetic effects. [26–28]…”

Section: Efficacy In Ucmentioning

confidence: 99%

Leukocyte apheresis in the management of ulcerative colitis

Helmy

Abdulla

Kagevi

et al. 2009

Saudi J Gastroenterol

View full text Add to dashboard Cite

Ulcerative colitis is a chronic inflammatory disease that affects the colon and rectum. Its pathogenesis is probably multifactorial including the influx of certain cytokines into the colonic mucosa, causing disease activity and relapse. The hypothesis of removing such cytokines from the circulation by leukocytapheresis was implemented to reduce disease activity, maintain remission, and prevent relapse. Many recent reports not only in Japan, but also in the West, have highlighted its beneficial effects in both adult and pediatric patients. Large placebo-controlled studies are needed to confirm the available data in this regard. In this article, we shed some light on the use of leukocyte apheresis in the management of autoimmune diseases, especially ulcerative colitis.

show abstract

“…2 patients were steroid-dependent and 2 were steroid-refractory. 2 of 4 (50%) patients showed an excellent response after 2 courses of Adacolumn; 1 patient showed a good response to 1 course of Adacolumn, but bloody stools persisted; in 1 patient Adacolumn was ineffective and total colectomy was performed [54]. …”

Section: Pediatric Inflammatory Bowel Diseasementioning

confidence: 99%

“…More recently, 4 pediatric UC patients (3 males and 1 female; aged 11–17 years) received 1 Adacolumn session/week for 5 consecutive weeks [54]. 3 patients had pancolitis and 1 had ulcerative proctitis.…”

Section: Pediatric Inflammatory Bowel Diseasementioning

confidence: 99%

Cytapheresis in Inflammatory Bowel Diseases: Current Evidence and Perspectives

Danese¹,

Angelucci²,

Stefanelli³

et al. 2008

Digestion

View full text Add to dashboard Cite

Ulcerative colitis and Crohn’s disease are inflammatory bowel diseases with a chronic relapsing course. Management of both conditions is far from being fully satisfactory. For this reason in the last decade a large number of biological therapies, targeting cytokines involved in intestinal inflammation, has been developed with various results in terms of efficacy, safety and costs. Activated granulocytes and monocytes represent the major sources of pro-inflammatory cytokines in the intestinal mucosa, playing a pivotal role in inducing and maintaining intestinal inflammation. Leukocytapheresis using an adsorptive carrier-based system (Adacolumn®) or a removal filter column (Cellsorba®) has been proposed as a feasible, safe and effective therapy for ulcerative colitis and Crohn’s disease. The objective of this paper is to provide an overview on the current knowledge about mechanisms of action, available clinical data and the possible future perspectives for the use of Adacolumn and Cellsorba in the management of inflammatory bowel diseases.

show abstract

Efficacy of Granulocyte Apheresis in Pediatric Patients With Ulcerative Colitis: A Pilot Study

Abstract: GCAP is effective in improving clinical symptoms and may play an important role in converting steroid therapy to other treatments in children with steroid-refractory or steroid-dependent ulcerative colitis.

Cited by 19 publications

References 11 publications

Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?

Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?

Leukocyte apheresis in the management of ulcerative colitis

Cytapheresis in Inflammatory Bowel Diseases: Current Evidence and Perspectives

Contact Info

Product

Resources

About

Efficacy of Granulocyte Apheresis in Pediatric Patients With Ulcerative Colitis: A Pilot Study

Abstract: GCAP is effective in improving clinical symptoms and may play an important role in converting steroid therapy to other treatments in children with steroid-refractory or steroid-dependent ulcerative colitis.

Cited by 19 publications

References 11 publications

Therapeutic landscape for ulcerative colitis: where is the Adacolumn&reg; system and where should it be?

Therapeutic landscape for ulcerative colitis: where is the Adacolumn&reg; system and where should it be?

Leukocyte apheresis in the management of ulcerative colitis

Cytapheresis in Inflammatory Bowel Diseases: Current Evidence and Perspectives

Contact Info

Product

Resources

About

Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?

Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?